

# Paul Beninger

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6245042/publications.pdf>

Version: 2024-02-01

21  
papers

188  
citations

1478280

6  
h-index

1125617

13  
g-index

21  
all docs

21  
docs citations

21  
times ranked

177  
citing authors

#	ARTICLE	IF	CITATIONS
1	Mind the gap: COVID-19 highlights the research void in pregnancy. American Journal of Obstetrics & Gynecology MFM, 2022, 4, 100566.	1.3	1
2	Need for a contingency dimension when planning vaccine development in a pandemic environment. Vaccine, 2022, 40, 2895-2896.	1.7	1
3	Who has not been vaccinated, fully vaccinated, or boosted for COVID-19?. American Journal of Infection Control, 2022, 50, 1185-1189.	1.1	12
4	Dynamic Dossier in the Cloud: A Sociotechnical Architecture for a Real-Time and Metrics-Based Data Tracking System with Gene and Cell Therapies as a Case Study. Therapeutic Innovation and Regulatory Science, 2021, 55, 388-400.	0.8	0
5	The Application of Engineering Principles and Practices to Medical Education: Preparing the Next Generation of Physicians. Medical Science Educator, 2021, 31, 897-904.	0.7	9
6	Review of FDA Amendments Act Section 921 Experience in Posting Data-mining Results from the FAERS Database. Clinical Therapeutics, 2021, 43, 380-395.	1.1	4
7	Influence of COVID-19 on the Pharmacovigilance Workforce of the Future. Clinical Therapeutics, 2021, 43, 369-371.	1.1	5
8	Signal Management in Pharmacovigilance: A Review of Activities and Case Studies. Clinical Therapeutics, 2020, 42, 1110-1129.	1.1	5
9	COVID-19: Regulatory Landscape of Medicinal and Medical Device Products for Human Use. Clinical Therapeutics, 2020, 42, 1444-1450.	1.1	15
10	Entrepreneurship for a meaningful clinical experience. BMJ Innovations, 2019, 5, 1-7.	1.0	4
11	Pharmacovigilance: Challenges in Getting From Here to There. Clinical Therapeutics, 2018, 40, 1964-1966.	1.1	4
12	Pharmacovigilance: An Overview. Clinical Therapeutics, 2018, 40, 1991-2004.	1.1	63
13	Risk Communication in a Pharmacovigilance Environment. Clinical Therapeutics, 2017, 39, 672-674.	1.1	2
14	Opportunities for Collaboration at the Interface of Pharmacovigilance and Manufacturing. Clinical Therapeutics, 2017, 39, 702-712.	1.1	12
15	Pharmacovigilance: Work in Progress. Pharmaceutical Medicine, 2017, 31, 1-5.	1.0	4
16	Data Sharing in the Pharmaceutical Enterprise: The Genie's Out of the Bottle. Clinical Therapeutics, 2017, 39, 1890-1894.	1.1	4
17	Theranos Experience Exposes Weaknesses in FDA Regulatory Discretion. Clinical Pharmacology in Drug Development, 2017, 6, 433-438.	0.8	1
18	Bridging the Academia/Industry Chasm: Proposed Solutions. Journal of Clinical Pharmacology, 2016, 56, 1457-1460.	1.0	1

#	ARTICLE	IF	CITATIONS
19	Pharmacovigilance and Biomedical Informatics: A Model for Future Development. <i>Clinical Therapeutics</i> , 2016, 38, 2514-2525.	1.1	40
20	Pharmacovigilance in the New Millennium. <i>Clinical Therapeutics</i> , 2016, 38, 2512-2513.	1.1	1
21	Medical Schoolsâ€™ Competition for Clinical Training Sites. <i>Academic Medicine</i> , 2016, 91, 1588-1588.	0.8	0